Optimal Post-Operative Nalbuphine Dose Regimen: A Randomized Controlled Trial in Patients with Laparoscopic...

Area of Science:

• Anesthesiology
• Pharmacology
• Surgical Pain Management

Background:

• Optimal post-operative analgesia aims for effective pain relief without adverse effects.
• Nalbuphine, a partial mu-opioid antagonist and kappa-opioid agonist, is a potential option for managing pain after laparoscopic surgery.
• Laparoscopic cholecystectomy patients require effective pain management strategies.

Purpose of the Study:

• To determine the appropriate nalbuphine dosage for post-operative pain control in patients undergoing laparoscopic cholecystectomy.
• To evaluate the efficacy and safety of different nalbuphine loading doses (0.05, 0.10, and 0.20 mg/kg) for post-operative pain.
• To assess nalbuphine consumption, pain scores, patient satisfaction, and adverse events.

Main Methods:

• A randomized study involving three groups receiving low (0.05 mg/kg), medium (0.10 mg/kg), or high (0.20 mg/kg) nalbuphine loading doses via patient-controlled analgesia.
• A 7-minute lockout interval was used for each bolus dose, with no background infusion.
• Primary outcomes included post-operative pain scores and nalbuphine consumption; secondary outcomes were opioid-related adverse events and patient satisfaction.

Main Results:

• The low-nalbuphine dose group (0.05 mg/kg) reported higher initial pain scores within the first two hours post-operation compared to medium and high dose groups (p=0.039).
• The low-nalbuphine dose group consumed less medication over four hours post-operation than the other groups (p=0.047).
• No significant differences were found in patient satisfaction scores or the incidence of adverse events across the dosage groups.

Conclusions:

• Nalbuphine dosages of 0.1 to 0.2 mg/kg are considered appropriate for initial post-operative pain management in the first four hours after laparoscopic cholecystectomy.
• A lower nalbuphine dosage of 0.05 mg/kg may be a viable option for post-operative pain management in this patient population.
• The study suggests a flexible approach to nalbuphine dosing based on individual patient needs and pain response.